There is no clear data on the cure rate of stage II membranous nephropathy treatment, but the prognosis is favorable through active treatment. Membranous nephropathy stage II is a pathologic diagnosis that refers to diffuse thickening of the glomerular basement membrane under electron microscopy, with subepithelial deposition of electron-dense material and formation of basement membrane pegs. Most patients present with a nephrotic syndrome of massive proteinuria, hypoproteinemia, edema, and hyperlipidemia. Some patients with membranous nephropathy resolve spontaneously, while treatment for others includes symptomatic and immunosuppressive therapy. Symptomatic treatment includes rest, sodium intake restriction, diuresis, and ACEI/ARB drugs to reduce urinary protein; immunosuppressive therapy includes hormones such as prednisone and cytotoxicity such as cyclophosphamide. The long-term prognosis of the patients was good overall, and the prognosis was relatively poor for patients who were accompanied by serious complications, such as persistent proteinuria. Patients diagnosed with membranous nephropathy after examination are advised to go to the hospital in time for active treatment under doctor’s guidance and regular review to avoid progression of the disease.